NCT02961166View on ClinicalTrials.gov

Immunglobulin M Enriched Intra Venous Immunoglobulin (IVIG) Therapy in Adult Respiratory Distress Syndrom (ARDS) Patients

CompletedOBSERVATIONAL
Enrollment

57

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

January 31, 2016

Study Completion Date

May 31, 2016

Conditions
Respiratory Distress Syndrome, AdultSeptic Shock
Interventions
DRUG

IgM enriched Immunoglobulins

Treatment for 3 days

Trial Locations (1)

72076

University Hospital Tuebingen, Tübingen

All Listed Sponsors
collaborator

Universität Tübingen

OTHER

lead

University Hospital Tuebingen

OTHER

NCT02961166 - Immunglobulin M Enriched Intra Venous Immunoglobulin (IVIG) Therapy in Adult Respiratory Distress Syndrom (ARDS) Patients | Biotech Hunter | Biotech Hunter